Contraception January - June 1991: Vol 43 Index

9 Pages·1.3 MB·English

CONTRACEPTION
AUTHOR INDEX
Volume 43
January to June 1991
Adoni, A, 77 Fang, R-y, 287
Albert, A.E., 167 Farr, G., 229
Albring, M., 101 Fioretti, P., 23
Andersch, B., 111 Fruzzetti, F., 23
Andrade, A.T.L., 241 Gates, D., 33
Ansari, A.S., 187,485 Gennarelli, G.L., 423
Ansbacher, N.«,; 139 Gerofi, J., 177
Antunez, O., 45 Goldenberg, R.L., 325
Apelo, R., 33 Goodson, P., 121
Aravena, R., 335 Graves, W., 167
Atsma, W.J., 23 Green, A., 653
Back, Did., 305, 317 Green, S., 305
Barcellona, P.S., 485 Haeberli, A., 435
Baudhuin, P., 387 Haller, H., 229
Belsey, E.M., 241, 361, Hardy, E., 121
375, 387, 401 Hatcher, R.A., 167
Ben Chetrit, A., 77 Heimann, S., 1
Bhaduri, A.P., 507 Hourihan, H., 361, 375
Bhat, N., 507 Inauen, W., 435
Boeck, L., 45 Jackson, J.R., 325
Bordon, R., 423 Jayaprakash, D., 187
Brill, K., 101 Johannisson, E., 361, 459
Brinton, L.A., 581 Jonsson, B., 447
Brosens, I., 361, 375, 387 Jutting, G., 1
Bunce, S., 33 Kamboj, V.P., 507
Buytaert, Ph., 413 Kaur, J., 83, 295
Cardenas, H., 335 Kim-Bjorklund, T., 459
Carta, @., 423 K 4g, ReJ-Bs, 527
Casado, M.E., 335 Klipping, C.0., 1
Cerza, S., 251 Knuppen, R., 1
Chakraborty, S., 273 Kohler, C.L., 325
Chi, E=-c, 33 Kumar, M., 187
Chretien, F.C., 55 Lammers, P., 23
Cornillie, F., 361, 387 Landgren, B-M, 149, 447, 459
Courtoy, P.J., 387 Lasso de la Vega, J., 33
Croxatto, H.B., 335 Lawson, J.P., 129
Croxtall, J.D., 401 Lohiya, N.K., 187, 485
Csemiczky, G., 149 Mahato, S.B., 475
Custo, ¢., 251 Mant, T., 317
d’Arcangues, C., 361, 401 Marbaix, E., 387
D{az, S., 335 Martin, C., 317
Diaz-S&nchez, V., 45 Mehrotra, P.K., 507
Dibbelt, L., 1 Melis, G.B., 23
Diczfalusy, E., 201 Merchant, P., 67
Donovan, B., 177 Millar, E., 317
Dubois, R., 55 Milne, R., 667
Dwivedi, A., 507 Milsom, I., 111
Elder, M., 129, 361, 401 Miranda, P., 335
Elstein, M., 129 Mirghani, O.A., 353
Eneroth, P., 447 Morrison, P., 317
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Nicoletti, I., 23 Shahani, S., 67
Noguera, M., 45 Sharma, D.N., 83
Norpetn, T., 101 Sharma, K., 187
Nuttall, I.D., 129 Sharma, S., 187
Orme, M., 305, 317 Shaw, S.T., JF, 241
Pakrashi, A, 273, 475 Shelley, G., 177
Pai, B.C., 475 Sheppard, B., 361, 375
Panser, L.A., 91 Shukla, R., 507
Parikka-Olexik, H., 1 Skegg, D.C.G., 521
Patel, K.L., 67 Souza, J.P., 241
Patel, L., 401 Srivastava, R.P., 507
Perovic, M., 229 Stanford, J.L., 543
Phipps, W.R., 91 Straub, P.W., 435
Pruthi, J.S., 83 Sullivan, M.H.F., 401
Qian, L-j, 263 Sundell, G., 111
Rajalakshmi, M., 83, 295 Taha, A.Z.,, 3253
Ramakrishnan, P.R., 83, 295 Tena, L.B., 497
Ramos, R., 33 Thomas, D.B., 597, 695
Randic, L., 229 Te Top SLT
Ray, H., 475 Trossarelli, G.F., 423
Renier, M., 413 Vargas, L., 45
Ricei, C., 23 Vessey, M., 667
Richards, J.M., dr., 325 Volpec, R., 251
Rivera, R., 33 Ward, S., 305
Rosenberg, L., 643 Weng, L-j, 263
Rowe, P.J., 241 White, J., 361, 401
Ryan, W.G., 325 xu, D., 263
Saitte, ¢C., 251 Yang, B-z, 287
Saltzman, W.M., 497 Yang, J., 161
Sang, G-w, 263 Zhang, J-y, 263
Schiappacasse, V., 335 Zhang, Y-p, 287
Schlesselman, J.J., 557 Zhao, Z., 161
Schnitker, J., 101 Zheng, H-z, 263
Scoccia, G., 251 Zhou, H-j, 287
Seth, M., 507
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
SUBJECT INDEX
Volume 43
January-June, 1991
Acacia auriculiformis triterpene saponins, effect on sperm
motility, 475
Accessory gland function,
effect of 20 Aet-1 (monkey), 83
effect of testosterone enanthate (monkey), 83
Adenomatous hyperplasia, relation to oral contraception, 557
20: Aet-1 (testosterone-trans-4-n-butyl cyclohexyl-carboxylate)
Antifertility effect, Malvaviscus conzattii flower extract (male
rat), 273
Arachidonic acid metabolite production, effect of levonorgestrel,
401
Attitudes of rural mothers toward family spacing methods, 353
Benign breast disease, relation of OC use and risk of breast
cancer, 597
Benzalkonium chloride, permeation through biocompatible polymers,
497
Bile and gallbladder function, effect of OC use, 667
Bioavailability,
ethinylestradiol, 45
eutectic ethinylestradiol-cholesterol, 45
Biochemical changes, effect of Malvaviscus conzattii flower
extract (male rat), 273
Biochemical effects, use of ethinyl estradiol + desogestrel, 435
Biocompatible polymers, spermicide permeation, 497
Bioequivalence testing for therapeutic equivalence of oral
contraceptives, 139
Biological profile, use of compound 85/83 (hamster, rat), 507
Biological testing, use of triterpene saponins from Acacia
auriculiformis, 475
Bleeding pattern,
use of ethinylestradiol + gestodene, 101, 413
use of ethinylestradiol + levonorgestrel, 263
Blood coagulation, effect of ethinyl estradiol + desogestrel, 435
Blood-subendothelium interaction, effect of ethinyl estradiol +
desogestrel, 435
Body iron stores and menstrual blood loss, 241
Brand-name vs generic oral contraceptives, bioequivalence
testing, 139
Breakage of condoms during use, 167
Breakage of condoms in use, relationship of tensile testing, 177
Breast, contraceptive agents and neoplasia, 527
Breast cancer,
relation to formulations and constituents of oral
contraceptives, 597
relative risk estimates in relation to OC use, 597
relative risk estimates in relation to OC use in developing
and developed countries, 695
Breast cancer and oral contraceptives, epidemiologic review, 597
Buserelin, alone or in combination with testosterone enanthate,
antispermatogenic activity, reversibility and toxicity
(monkey), 197
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Carbohydrate metabolism, effect of ethinylestradiol + gestodene,
423
CBG (corticosteroid-binding globulin)
CBG level,
effect of ethinyl estradiol + desogestrel, 1
effect of ethinyl estradiol + gestodene, 1
Cervical adenocarcinoma, relationship to oral contraceptives, 581
Cervical carcinoma, relative risk estimates in relation to OC use
in developing and developed countries, 695
Cervical mucus, effect of nomegestrol acetate, 55
Cervical mucus composition, effect of various IUDs, 447
Cervical neoplasia,
relationship to oral contraceptives, 581
relative risk estimates in relation to OC use, 581
Cervix, contraceptive agents and neoplasia, 527
Chlorhexidine, permeation through biocompatible polymers, 497
Cholangiocarcinoma,
relation to OC use, 643
relative risk estimates in relation to OC use in developing
and developed countries, 695
Clinical chemistry,
effect of Buserelin (monkey), 187
effect of Buserelin + testosterone enanthate (monkey), 187
Clinical experience, use of ethinylestradiol + gestodene, 101
Clinical investigations, use of tolnidamine (monkey), 485
Clinical study,
copper-bearing Lippes Loop, 229
Lippes Loop, 229
Coagulatory factors, effect of ethinylestradiol dose in oral
contraceptives, 23
Colon cancer, relationship to OC use, 667
Colorectal/rectal cancer,
relationship to OC use, 667
relative risk estimates in relation to OC use, 667
Complaints, use of levonorgestrel-releasing intravaginal ring,
129
Compound 85/83 (3-amino-6,7-dimethoxy-1H-pyrazolo [3,4-b]
quinoline, effect on pregnancy (guinea pig, hamster,
rat), 507
Condom use and breakage, 167
Condoms,
breakage rates, 167
motivation for use, 167
relationship between tensile testing and breakage in use,
177
Contraception and pregnancy outcome, 111
Contraceptive efficacy, lactational amenorrhea, 335
Contraceptive method accepted and perception of information
received, 121
Contraceptive methods currently in use, 201
Contraceptive practices, rural village settings, 353
Contraceptive prevalence, reproductive health and future, 201
Copper-bearing Lippes Loop, clinical study, 229
Copper-containing Nova-T, effect on composition of cervical
mucus, 447
Corpus luteum, effect of norethisterone, 459
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Cutaneous melanoma,
relation to OC use, 653 |
relative risk estimates in relation to OC use, 653
Cyproterone acetate, effect on epididymis and spermatozoa
(monkey), 295
Developed vs developing countries,
influence of OC use on risk of neoplasms, 695
relationship between OC use and breast cancer, 597
Discontinuations,
oc use, 111
use of ethinyl oestradiol + gestodene, 413
use of levonorgestrel-releasing intravaginal ring, 129
DL111-IT (3-(2-ethyl phenyl) -5-(3-methoxy phenyl) -1H-1,2,4-
triazole), subsequent embryotoxic and teratogenic
effects (rat), 287
Duration of OC use and relation to risk of breast cancer, 597
Effectiveness, use of ethinyl oestradiol + gestodene, 413
Efficacy, use of ethinylestradiol + gestodene, 101
Embryotoxicity, subsequent gestation after administration of
DL111-IT (rat), 287
Endocrine parameters, effect of &8-hCG vaccine formulations, 67
Endometrial arachidonic acid metabolites, effect of
levonorgestrel, 401
Endometrial cancer,
relative risk estimates in relation to OC use, 557
relative risk estimates in relation to OC use in developing
and developed countries, 695
Endometrial lysosomal enzymes, effect of levonorgestrel, 387
Endometrial morphology,
effect of levonorgestrel, 361
effect of norethisterone, 459
Endometrial vasculature, effect of levonorgestrel, 375
Endometriun,
contraceptive agents and neoplasia, 527
effect of norethisterone, 459
oral contraceptives and neoplasia, 557
Environmental health and reproductive health, 201
Epididymal tubules culture system (monkey), 295
Epididymis, effect of cyproterone acetate (monkey), 295
Estrogen action, relevant to neoplasia, 527
Estrogen replacement therapy, risk of endometrial cancer, 557
Ethinylestradiol, absorption study, 45
Ethinyl estradiol + desogestrel,
effect of deliberate omission of pill intake, 149
effect on blood coagulation and thrombogenesis, 435
effect on coagulatory factors, 23
effect on SHBG and CBG levels, 1
high and low estrogen dose, 435
pharmacokinetic parameters for ethinyl estradiol, 1
Ethinyl estradiol + gestodene,
clinical experience, 101
Clinical trial, 413
effect on carbohydrate metabolism, 423
effect on coagulatory factors, 23
effect on SHBG and CBG levels, 1
pharmacokinetic parameters for ethinyl estradiol, 1
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Ethinyl estradiol + levonorgestrel,
clinical experience, 263
effect of deliberate omission of pill intake, 149
effect-on coagulatory factors, 23
Ethinylestradiol dose in oral contraceptives, effect on
haemostatic system, 23
Ethinyl estradiol level,
following ethinyl estradiol + desogestrel, 1
following ethinyl estradiol + gestodene, 1
Ethinylestradiol-cholesterol eutectic combination, absorption
study, 45
Ethynylestradiol, pharmacokinetics, 305
Ethynylestradiol + desogestrel, effect on pharmacokinetics of
ethynylestradiol, 305
Ethynylestradiol + gestodene, effect on pharmacokinetics of
ethynylestradiol, 305
Ethynylestradiol + levonorgestrel, interaction with temafloxacin,
Sat
Fallopian tube, effect of norethisterone, 459
Family spacing attitudes and practices, 353
Filshie clip via minilaparotomy, postpartum tubal sterilization,
33
Follicular growth,
effect of ethinylestradiol + desogestrel, 149
effect of ethinylestradiol + levonorgestrel, 149
Gallbladder cancer, relative risk estimates in relation to OC use
in developing and developed countries, 695
Gallbladder-extrahepatic bile duct cancer,
relationship to OC use, 667
relative risk estimates in relation to OC use, 667
Generic vs brand-name oral contraceptives, bioequivalence
testing, 139
Haemostatic system, effect of ethinylestradiol dose in oral
contraceptives, 23
B-hCG vaccines, effect on endocrine parameters, 67
Hematologic effects, use of ethinyl estradiol + desogestrel, 435
Hematologic indices and menstrual blood loss, effect of OC use,
241
Hepatocellular adenoma, relation to OC use, 643
Hepatocellular carcinoma, relation to OC use, 643
Hormonal levels, effect of &-hCG vaccine formulations, 67
Hormonal profile,
compound 85/83 (rat), 507
effect of Malvaviscus conzattii flower extract (male rat),
273
Implant contraceptive, levonorgestrel, 121
Interchangeability of oral contraceptives, generic vs brand-name
products, 139
Intrauterine device (IUD),
Anticon, 251
copper T, 251
copper-bearing Lippes Loop, 229
copper-containing Nova-T, 447
Gravigard, 251
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
levonorgestrel-releasing Nova-T, 447
Lippes Loop D, 229
management following uterine perforation, 77
mechanical resistance assessment, 251
Nova-T, 251, 447
TCu 200, 121
IUD (intrauterine device)
Kidney cancer, relationship to OC use, 667
Lactational amenorrhea, contraceptive efficacy, 335
Levonorgestrel-releasing Nova-T, effect on composition of
cervical mucus, 447
Levonorgestrel-releasing vaginal ring,
effect on endometrial vascular features, 375
effect on endometrium, 361
effect on lysosomal enzymes in endometrium, 387
efficacy and acceptability, 129
prostaglandin production in endometrium, 401
LH-RH (luteinizing hormone-releasing hormone)
LH-RH agonist, Buserelin, 187
Lippes Loop D, clinical study, 229
Liver, oral contraceptives and neoplasia, 527, 643
Liver cancer,
relative risk estimates in relation to OC use, 643
relative risk estimates in relation to OC use in developing
and developed countries, 695
Luteal function,
effect of ethinylestradiol + desorgestrel, 149
effect of ethinylestradiol + levonorgestrel, 149
Lysosomal enzymes in endometrium, effect of levonorgestrel, 387
Malvaviscus conzattii flower extract, effect on fertility (male
Frat), 273
Mast cell numbers, effect of levonorgestrel, 375
Mechanical resistance assessment, IUDs, 251
Melanocytic nevi, relation to OC use, 653
Melanoma,
effect of steroid hormones, 653
relation to OC use, 653
Menstrual blood loss and body iron stores, 241
Menstrual status postpartum, effect on probability of pregnancy,
335
Mental health, impact of tubal sterilization, 325
Neoplasia and oral contraceptives, 521, 527, 543, 557, 581, 597,
643, 653, 557, 695
Neoplasms, influence of OC use on risk in developing and
developed countries, 695
Nomegestrol acetate, effect on cervical mucus, 55
Nonoxynol-9,
permeation through biocompatible polymers, 497
quantitative analysis in blood, 161
Nonoxynol-9-releasing vaginal ring, 497
Norethisterone, effect on endometrium, Fallopian tube and corpus
luteum, 459
NorplantF, study of acceptors, 121
Nova-T, effect on composition of cervical mucus, 447
Nursing status, effect on probability of pregnancy, 335
oc (oral contraceptive)
Omission of oral contraceptive pill intake, effect on follicular
growth and luteal function, 149
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Oral contraceptive (OC),
ethinyl estradiol + desogestrel, 1, 23, 149, 435
ethinyl estradiol + gestodene, 1, 23, 101, 413, 423
ethynylestradiol + levonorgestrel, 317
norethisterone, 459
triphasic ethinylestradiol + levonorgestrel, 23, 149, 263
Oral contraceptive use, effect on pelvic inflammatory disease, 91
Oral contraceptives, bioequivalence testing for therapeutic
equivalence, 139
Oral contraceptives and neoplasia, 521, 527, 543, 557, 581, 597,
643, 653, 667, 695
Organ culture of epididymal tubules (monkey), 295
Ovarian cancer,
relative risk estimates in relation to OC use, 543
relative risk estimates in relation to OC use in developing
and developed countries, 695
Ovary, contraceptives and neoplasia, 527, 543
Pelvic inflammatory disease, effect of OC use, 91
Perception of information received and contraceptive method
accepted, 121
Permeation through biocompatible polymers, spermicides, 497
Pharmacokinetics,
ethinyl estradiol, 1, 45, 305
eutectic ethinylestradiol-cholesterol, 45
Pituitary disorders, relationship to OC use, 667
Pituitary tumours,
relationship to OC use, 667
relative risk estimates in relation to OC use, 667
Pituitary-ovarian axis, effect of B-hCG vaccine formulations, 67
Postpartum tubal sterilization, 33
Pregnancy, effect of compound 85/83 (guinea pig, hamster, rat),
507
Pregnancy history and prevalence of contraception, 111
Pregnancy probability,
according to postpartum menstrual status, 335
nursing women, 335
Pregnancy rate, postpartum tubal sterilization, 83
Progestin action, relevant to neoplasia, 527
Progestins, potency, 527
Prostaglandin production in endometrium, effect of
levonorgestrel, 401
Psychosocial impact, tubal sterilization, 325
Reproductive health, 201
Resistance to mechanical fatigue, IUDs, 251
Risk factors, influence on oral contraceptives and breast cancer,
597
SHBG (sex hormone-binding globulin)
SHBG level,
effect of ethinyl estradiol + desogestrel, 1
effect of ethinyl estradiol + gestodene, 1
Side effects,
use of ethinyl estradiol + desogestrel, 435
use of ethinylestradiol + gestodene, 101, 413
use of ethinylestradiol + levonorgestrel, 263
Skin neoplasia and oral contraceptives, 653
Sperm motility, effect of triterpene saponins from Acacia
auriculiformis, 475
JUNE 1991 VOL. 43 NO. 6
CONTRACEPTION
Spermatogenesis,
effect of Buserelin (monkey), 187
effect of Buserelin + testosterone enanthate (monkey), 187
effect of Malvaviscus conzattii flower estract (rat), 271
effect of tolnidamine (monkey), 485
Spermatozoa,
effect of cyproterone acetate (monkey), 295
effect of triterpene saponins from Acacia auriculiformis,
475
Sterilization, tubal occlusion during postpartum hospitalization,
33
TCu 200, study of acceptors, 121
Temafloxacin, interaction with ethynylestradiol + levonorgestrel,
Sue
Tensile testing, condoms, a
Teratogenecity, subsequent. gestation after administration of
DL111-IT (rat), 287
Terminations, use of ethinylestradiol + levonorgestrel, 263
Testes,
effect of Buserelin (monkey), 187
effect of Buserelin + testosterone enanthate (monkey), 187
effect of tolnidamine (monkey), 485
Testosterone enanthate, effect on accessory gland (monkey), 83
Testosterone-trans-4-n-butyl cyclohexyl-carboxylate (20 Aet-1),
effect on accessory gland function (monkey), 83
Thrombogenesis, effect of ethinyl estradiol + desogestrel, 435
Time in woman’s life OC use initiated and relation to risk of
breast cancer, SS?
Tissue plasminogen activator, effect of levonorgestrel, 375
Tolnidamine (1-[ (4-chloro-2-memtethhyyl ]l-p1Hh-iendnazyol1e-)3-
carboxylic acid), effect on spermatogenesis (monkey),
485
Translocation of an IUD, management, 77
Triphasic ethinylestradiol + levonorgestrel,
clinical experience, 263
effect of deliberate omission of pill intake, 149
effect on coagulatory factors, 23
Tubal sterilization,
postpartun, aa
psychosocial impact, 325
Uterine corpus, oral contraceptives and neoplasia, 557
Uterine fibroids, effect of oral contraceptives, 557
Uterine perforation by an IUD, management, 77
Uterine sarcoma,
relation to oral contraception, 557
relative risk estimates in relation to OC use in developing
and developed countries, 695
Vaginal ring,
releasing levonorgestrel, 129, 361, 375, 387, 401
releasing nonoxynol-9, 497
Vascular subendothelium (rabbit) exposed to flowing blood, effect
of ethinyl estradiol + desogestrel, 435
JUNE 1991 VOL. 43 NO. 6